Versant Venture Capital V (Canada), LP 4

Accession 0001104659-18-046292

CIK 0001658247other

View on SEC.gov Company Profile

Filed

Jul 19, 8:00 PM ET

Accepted

Jul 20, 4:34 PM ET

Size

44.5 KB

Accession

0001104659-18-046292

Insider Transaction Report

Form 4

Period: 2018-07-20

Crinetics Pharmaceuticals, Inc.CRNX

Versant Venture Capital V, L.P.

10% Owner

Transactions

Conversion
Common Stock
2018-07-20+76,927→ 76,927 total(indirect: See Footnotes)
Conversion
Common Stock
2018-07-20+85,253→ 85,253 total(indirect: See Footnotes)
Conversion
Common Stock
2018-07-20+194,629→ 194,629 total(indirect: See Footnotes)
Conversion
Common Stock
2018-07-20+412,534→ 2,969,926 total(indirect: See Footnotes)
Conversion
Common Stock
2018-07-20+13,736→ 98,989 total(indirect: See Footnotes)
Conversion
Series A Preferred Stock
2018-07-20−8,413,817→ 0 total(indirect: See Footnotes)
→ Common Stock (2,557,392 underlying)
Conversion
Series B Preferred Stock
2018-07-20−1,357,240→ 0 total(indirect: See Footnotes)
→ Common Stock (412,534 underlying)
Conversion
Common Stock
2018-07-20+2,557,392→ 2,557,392 total(indirect: See Footnotes)
Conversion
Series A Preferred Stock
2018-07-20−253,091→ 0 total(indirect: See Footnotes)
→ Common Stock (76,927 underlying)
Conversion
Series A Preferred Stock
2018-07-20−640,332→ 0 total(indirect: See Footnotes)
→ Common Stock (194,629 underlying)
Conversion
Series B Preferred Stock
2018-07-20−40,826→ 0 total(indirect: See Footnotes)
→ Common Stock (12,409 underlying)
Conversion
Series B Preferred Stock
2018-07-20−45,192→ 0 total(indirect: See Footnotes)
→ Common Stock (13,736 underlying)
Conversion
Series B Preferred Stock
2018-07-20−103,293→ 0 total(indirect: See Footnotes)
→ Common Stock (31,396 underlying)
Conversion
Common Stock
2018-07-20+12,409→ 89,336 total(indirect: See Footnotes)
Conversion
Common Stock
2018-07-20+31,396→ 226,025 total(indirect: See Footnotes)
Conversion
Series A Preferred Stock
2018-07-20−280,485→ 0 total(indirect: See Footnotes)
→ Common Stock (85,253 underlying)

Versant Affiliates Fund V, L.P.

10% Owner

Transactions

Conversion
Common Stock
2018-07-20+2,557,392→ 2,557,392 total(indirect: See Footnotes)
Conversion
Common Stock
2018-07-20+76,927→ 76,927 total(indirect: See Footnotes)
Conversion
Common Stock
2018-07-20+85,253→ 85,253 total(indirect: See Footnotes)
Conversion
Common Stock
2018-07-20+412,534→ 2,969,926 total(indirect: See Footnotes)
Conversion
Common Stock
2018-07-20+31,396→ 226,025 total(indirect: See Footnotes)
Conversion
Series A Preferred Stock
2018-07-20−280,485→ 0 total(indirect: See Footnotes)
→ Common Stock (85,253 underlying)
Conversion
Series B Preferred Stock
2018-07-20−1,357,240→ 0 total(indirect: See Footnotes)
→ Common Stock (412,534 underlying)
Conversion
Series B Preferred Stock
2018-07-20−45,192→ 0 total(indirect: See Footnotes)
→ Common Stock (13,736 underlying)
Conversion
Series B Preferred Stock
2018-07-20−103,293→ 0 total(indirect: See Footnotes)
→ Common Stock (31,396 underlying)
Conversion
Common Stock
2018-07-20+194,629→ 194,629 total(indirect: See Footnotes)
Conversion
Common Stock
2018-07-20+12,409→ 89,336 total(indirect: See Footnotes)
Conversion
Common Stock
2018-07-20+13,736→ 98,989 total(indirect: See Footnotes)
Conversion
Series A Preferred Stock
2018-07-20−8,413,817→ 0 total(indirect: See Footnotes)
→ Common Stock (2,557,392 underlying)
Conversion
Series A Preferred Stock
2018-07-20−253,091→ 0 total(indirect: See Footnotes)
→ Common Stock (76,927 underlying)
Conversion
Series A Preferred Stock
2018-07-20−640,332→ 0 total(indirect: See Footnotes)
→ Common Stock (194,629 underlying)
Conversion
Series B Preferred Stock
2018-07-20−40,826→ 0 total(indirect: See Footnotes)
→ Common Stock (12,409 underlying)

Versant Venture Capital V (Canada), LP

10% Owner

Transactions

Conversion
Common Stock
2018-07-20+412,534→ 2,969,926 total(indirect: See Footnotes)
Conversion
Series A Preferred Stock
2018-07-20−8,413,817→ 0 total(indirect: See Footnotes)
→ Common Stock (2,557,392 underlying)
Conversion
Series A Preferred Stock
2018-07-20−280,485→ 0 total(indirect: See Footnotes)
→ Common Stock (85,253 underlying)
Conversion
Series B Preferred Stock
2018-07-20−1,357,240→ 0 total(indirect: See Footnotes)
→ Common Stock (412,534 underlying)
Conversion
Series B Preferred Stock
2018-07-20−40,826→ 0 total(indirect: See Footnotes)
→ Common Stock (12,409 underlying)
Conversion
Series B Preferred Stock
2018-07-20−103,293→ 0 total(indirect: See Footnotes)
→ Common Stock (31,396 underlying)
Conversion
Common Stock
2018-07-20+76,927→ 76,927 total(indirect: See Footnotes)
Conversion
Common Stock
2018-07-20+12,409→ 89,336 total(indirect: See Footnotes)
Conversion
Series A Preferred Stock
2018-07-20−253,091→ 0 total(indirect: See Footnotes)
→ Common Stock (76,927 underlying)
Conversion
Common Stock
2018-07-20+2,557,392→ 2,557,392 total(indirect: See Footnotes)
Conversion
Common Stock
2018-07-20+194,629→ 194,629 total(indirect: See Footnotes)
Conversion
Common Stock
2018-07-20+31,396→ 226,025 total(indirect: See Footnotes)
Conversion
Common Stock
2018-07-20+85,253→ 85,253 total(indirect: See Footnotes)
Conversion
Common Stock
2018-07-20+13,736→ 98,989 total(indirect: See Footnotes)
Conversion
Series A Preferred Stock
2018-07-20−640,332→ 0 total(indirect: See Footnotes)
→ Common Stock (194,629 underlying)
Conversion
Series B Preferred Stock
2018-07-20−45,192→ 0 total(indirect: See Footnotes)
→ Common Stock (13,736 underlying)

Versant Ophthalmic Affiliates I, L.P.

10% Owner

Transactions

Conversion
Common Stock
2018-07-20+2,557,392→ 2,557,392 total(indirect: See Footnotes)
Conversion
Common Stock
2018-07-20+76,927→ 76,927 total(indirect: See Footnotes)
Conversion
Common Stock
2018-07-20+85,253→ 85,253 total(indirect: See Footnotes)
Conversion
Common Stock
2018-07-20+194,629→ 194,629 total(indirect: See Footnotes)
Conversion
Common Stock
2018-07-20+412,534→ 2,969,926 total(indirect: See Footnotes)
Conversion
Common Stock
2018-07-20+12,409→ 89,336 total(indirect: See Footnotes)
Conversion
Common Stock
2018-07-20+13,736→ 98,989 total(indirect: See Footnotes)
Conversion
Common Stock
2018-07-20+31,396→ 226,025 total(indirect: See Footnotes)
Conversion
Series A Preferred Stock
2018-07-20−280,485→ 0 total(indirect: See Footnotes)
→ Common Stock (85,253 underlying)
Conversion
Series B Preferred Stock
2018-07-20−1,357,240→ 0 total(indirect: See Footnotes)
→ Common Stock (412,534 underlying)
Conversion
Series B Preferred Stock
2018-07-20−103,293→ 0 total(indirect: See Footnotes)
→ Common Stock (31,396 underlying)
Conversion
Series A Preferred Stock
2018-07-20−8,413,817→ 0 total(indirect: See Footnotes)
→ Common Stock (2,557,392 underlying)
Conversion
Series A Preferred Stock
2018-07-20−253,091→ 0 total(indirect: See Footnotes)
→ Common Stock (76,927 underlying)
Conversion
Series A Preferred Stock
2018-07-20−640,332→ 0 total(indirect: See Footnotes)
→ Common Stock (194,629 underlying)
Conversion
Series B Preferred Stock
2018-07-20−40,826→ 0 total(indirect: See Footnotes)
→ Common Stock (12,409 underlying)
Conversion
Series B Preferred Stock
2018-07-20−45,192→ 0 total(indirect: See Footnotes)
→ Common Stock (13,736 underlying)

Footnotes (6)

[F1]The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 3.29 to 1 share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date.
[F2]These securities are held of record by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. Samuel D. Colella, William J. Link, Bradley Bolzon, Ph.D., Robin L. Praeger, Kirk G. Nielson and Thomas Woiwode, Ph.D. are managing directors of VV V and share voting and dispositive power over the shares held by VVC V; however, they each disclaim beneficial ownership of the shares held by VVC V, except to the extent of their pecuniary interests therein.
[F3]These securities are held of record by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. Samuel D. Colella, William J. Link, Bradley Bolzon, Ph.D., Robin L. Praeger, Kirk G. Nielson and Thomas Woiwode, Ph.D. are managing directors of VV V and share voting and dispositive power over the shares held by VAF V; however, they each disclaim beneficial ownership of the shares held by VAF V, except to the extent of their pecuniary interests therein.
[F4]These securities are held of record by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"). VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. Samuel D. Colella, William J. Link, Bradley Bolzon, Ph.D., Robin L. Praeger, Kirk G. Nielson and Thomas Woiwode, Ph.D. are managing directors of VV V and share voting and dispositive power over the shares held by VOA; however, they each disclaim beneficial ownership of the shares held by VOA, except to the extent of their pecuniary interests therein.
[F5]These securities are held of record by Versant Venture Capital V (Canada) LP ("VVC CAN"). Versant Ventures V (Canada) GP-GP, Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), LP ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. By virtue of such relationships, VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. Samuel D. Colella, William J. Link, Bradley Bolzon, Ph.D., Robin L. Praeger, Kirk G. Nielson and Thomas Woiwode, Ph.D. are directors of VV V CAN GP and share voting and dispositive power over the shares held by VVC CAN; however, they each disclaim beneficial ownership of the shares held by VVC CAN, except to the extent of their pecuniary interests therein.
[F6]This report on Form 4 is jointly filed by VVC V, VAF V, VOA and VVC CAN. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

Documents

1 file

4
a4.xmlPrimary
4

Issuer

Crinetics Pharmaceuticals, Inc.

CIK 0001658247

→

Entity typeother

IncorporatedOntario, Canada

Related Parties

filerCIK 0001612235

Filing Metadata

Form type: 4
Filed: Jul 19, 8:00 PM ET
Accepted: Jul 20, 4:34 PM ET
Size: 44.5 KB

View on SEC.gov